Inflammation and Immunity in Hypertension

Hypertension: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2018, Pages 60-69

  Harrison, David G ^a   Bernstein, Kenneth E ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85054891641     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-42973-3.00007-X     Document Type: Chapter

References (83)

1. Muller W.A. The regulation of transendothelial migration: new knowledge and new questions. Cardiovasc Res. 2015, 107:310-320.
2. Riera Romo M., Perez-Martinez D., Castillo Ferrer C. Innate immunity in vertebrates: an overview. Immunology. 2016, 148:125-139.
3. Panda S., Ding J.L. Natural antibodies bridge innate and adaptive immunity. J Immunol. 2015, 194:13-20.
4. Ingersoll M.A., Platt A.M., Potteaux S., et al. Monocyte trafficking in acute and chronic inflammation. Trends Immunol. 2011, 32:470-477.
5. Hashimoto D., Chow A., Noizat C., et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013, 38:792-804.
6. Jakubzick C., Gautier E.L., Gibbings S.L., et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity. 2013, 39:599-610.
7. Abbas A., Lichtman A., Pillai S. Cellular and Molecular Immunology 2014, Elsevier Saunders, Philadelphia, PA. 8th ed.
8. Heptinstall R.H. Renal biopsies in hypertension. Br Heart J. 1954, 16:133-141.
9. White F.N., Grollman A. Autoimmune factors associated with infarction of the kidney. Nephron. 1964, 204:93-102.
10. Okuda T., Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med. 1967, 25:257-264.
11. Olsen F. Type and course of the inflammatory cellular reaction in acute angiotensin-hypertensive vascular disease in rats. Acta Pathol Microbiol Scand. A 1970, 78:143-150.
12. Olsen F. Inflammatory cellular reaction in hypertensive vascular disease in man. Acta Pathol Microbiol Scand. A. 1972, 80:253-256.
13. Svendsen U.G. Evidence for an initial, thymus independent and a chronic, thymus dependent phase of DOCA and salt hypertension in mice. Acta Pathol Microbiol Scand A. 1976, 84:523-528.
14. Olsen F. Transfer of arterial hypertension by splenic cells from DOCA-salt hypertensive and renal hypertensive rats to normotensive recipients. Acta Pathol Microbiol Scand C. 1980, 88:1-5.
15. Bendich A., Belisle E.H., Strausser H.R. Immune system modulation and its effect on the blood pressure of the spontaneously hypertensive male and female rat. Biochem Biophys Res Commun. 1981, 99:600-607.
16. Trott D.W., Thabet S.R., Kirabo A., et al. Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertension. 2014, 64:1108-1115.
17. Chan C.T., Sobey C.G., Lieu M., et al. Obligatory role for B cells in the development of angiotensin II-dependent hypertension. Hypertension. 2015, 66:1023-1033.
18. LaMarca B., Wallace K., Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr Opin Pharmacol. 2011, 11:175-179.
19. Wenzel P., Knorr M., Kossmann S., et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation. 2011, 124:1370-1381.
20. Kirabo A., Fontana V., de Faria A.P., et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014, 124:4642-4656.
21. Kossmann S., Schwenk M., Hausding M., et al. Angiotensin II-induced vascular dysfunction depends on interferon-gamma-driven immune cell recruitment and mutual activation of monocytes and NK-cells. Arterioscler Thromb Vasc Biol. 2013, 33:1313-1319.
22. Shah K.H., Shi P., Giani J.F., et al. Myeloid Suppressor Cells Accumulate and Regulate Blood Pressure in Hypertension. Circ Res. 2015, 117:858-869.
23. Guyton A.C. Renal function curve-a key to understanding the pathogenesis of hypertension. Hypertension. 1987, 10:1-6.
24. Derchi L.E., Leoncini G., Parodi D., et al. Mild renal dysfunction and renal vascular resistance in primary hypertension. Am J Hypertens. 2005, 18:966-971.
25. Gkaliagkousi E., Gavriilaki E., Triantafyllou A., et al. Clinical Significance of Endothelial Dysfunction in Essential Hypertension. Curr Hypertens Rep. 2015, 17:85.
26. De Keulenaer G.W., Alexander R.W., Ushio-Fukai M., et al. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J. 1998, 329(Pt 3):653-657.
27. Miller F.J., Filali M., Huss G.J., et al. Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res. 2007, 101:663-671.
28. Bobik A. The structural basis of hypertension: vascular remodeling, rarefaction and angiogenesis/arteriogenesis. J Hypertens. 2005, 23:1473-1475.
29. Mitchell G.F., Hwang S.J., Vasan R.S., et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010, 121:505-511.
30. Cooper L.L., Rong J., Benjamin E.J., et al. Components of hemodynamic load and cardiovascular events: the Framingham Heart Study. Circulation. 2015, 131:354-361. discussion 361.
31. Harwani S.C., Chapleau M.W., Legge K.L., et al. Neurohormonal modulation of the innate immune system is proinflammatory in the prehypertensive spontaneously hypertensive rat, a genetic model of essential hypertension. Circ Res. 2012, 111:1190-1197.
32. Madhur M.S., Lob H.E., McCann L.A., et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010, 55:500-507.
33. Nguyen H., Chiasson V.L., Chatterjee P., et al. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovasc Res. 2013, 97:696-704.
34. Shao J., Nangaku M., Miyata T., et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension. 2003, 42:31-38.
35. Crowley S.D., Song Y.S., Lin E.E., et al. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2010, 298:R1089-R1097.
36. Marko L., Kvakan H., Park J.K., et al. Interferon-gamma signaling inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension. 2012, 60:1430-1436.
37. Brands M.W., Banes-Berceli A.K., Inscho E.W., et al. Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation. Hypertension. 2010, 56:879-884.
38. Shi P., Diez-Freire C., Jun J.Y., et al. Brain microglial cytokines in neurogenic hypertension. Hypertension. 2010, 56:297-303.
39. Santisteban M.M., Ahmari N., Marulanda Carvajal J., et al. Involvement of bone marrow cells and neuroinflammation in hypertension. Circ Res. 2015, 113:178-191.
40. Pollow D.P., Uhrlaub J., Romero-Aleshire M.J., et al. Sex differences in T-lymphocyte tissue infiltration and development of angiotensin II hypertension. Hypertension. 2014, 64:384-390.
41. Lob H.E., Marvar P.J., Guzik T.J., et al. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension. 2010, 55:277-283.
42. Lob H.E., Schultz D., Marvar P.J., et al. Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension. 2013, 61:382-387.
43. Xiao L., Kirabo A., Wu J., et al. Renal Denervation Prevents Immune Cell Activation and Renal Inflammation in Angiotensin II-Induced Hypertension. Circ Res. 2015, 117:547-557.
44. Marvar P.J., Vinh A., Thabet S., et al. T lymphocytes and vascular inflammation contribute to stress-dependent hypertension. Biol Psychiatry. 2012, 71:774-782.
45. Jung O., Schreiber J.G., Geiger H., et al. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation. 2004, 109:1795-1801.
46. Landmesser U., Dikalov S., Price S.R., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003, 111:1201-1209.
47. Landmesser U., Cai H., Dikalov S., et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002, 40:511-515.
48. Gavazzi G., Banfi B., Deffert C., et al. Decreased blood pressure in NOX1-deficient mice. FEBS Lett. 2006, 580:497-504.
49. Cassatella M.A., Bazzoni F., Flynn R.M., et al. Molecular basis of interferon-gamma and lipopolysaccharide enhancement of phagocyte respiratory burst capability. Studies on the gene expression of several NADPH oxidase components. J Biol Chem. 1990, 265:20241-20246.
50. Manea A., Tanase L.I., Raicu M., et al. Jak/STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 2010, 30:105-112.
51. Pietrowski E., Bender B., Huppert J., et al. Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H-oxidase derived reactive oxygen species. J Vasc Res. 2011, 48:52-58.
52. Yan Q., Gao K., Chi Y., et al. NADPH oxidase-mediated upregulation of connexin43 contributes to podocyte injury. Free Radic Biol Med. 2012, 53:1286-1297.
53. Harrison D.G., Gongora M.C. Oxidative stress and hypertension. Med Clin North Am. 2009, 93:621-635.
54. Krstic J., Santibanez J.F. Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. ScientificWorldJournal. 2014, 2014:521754.
55. Wang M., Kim S.H., Monticone R.E., et al. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension. 2015, 65:698-703.
56. Wells J.M., Gaggar A., Blalock J.E. MMP generated matrikines. Matrix Biol. 2015, 44-46:122-129.
57. Meng X.M., Tang P.M., Li J., et al. TGF-beta/Smad signaling in renal fibrosis. Front Physiol. 2015, 6:82.
58. Seeger P., Musso T., Sozzani S. The TGF-beta superfamily in dendritic cell biology. Cytokine Growth Factor Rev. 2015, 26:647-657.
59. Wu J., Thabet S.R., Kirabo A., et al. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res. 2014, 114:616-625.
60. Meyrier A. Nephrosclerosis: update on a centenarian. Nephrol Dial Transplant. 2015, 30:1833-1841.
61. Sakai N., Wada T., Yokoyama H., et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci USA. 2006, 103:14098-14103.
62. Bucala R., Spiegel L.A., Chesney J., et al. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med. 1994, 1:71-81.
63. Wu J., Montaniel K.R., Saleh M.A., et al. The origin of matrix-producing cells that contribute to aortic fibrosis in hypertension. Hypertension. 2016, 67:461-468.
64. Guzik T.J., Hoch N.E., Brown K.A., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007, 204:2449-2460.
65. Liu Y., Mei J., Gonzales L., et al. IL-17A and TNF-alpha exert synergistic effects on expression of CXCL5 by alveolar type II cells in vivo and in vitro. J Immunol. 2011, 186:3197-3205.
66. Yuan S., Zhang S., Zhuang Y., et al. Interleukin-17 Stimulates STAT3-Mediated Endothelial Cell Activation for Neutrophil Recruitment. Cell Physiol Biochem. 2015, 36:2340-2356.
67. Wu J., Saleh M.A., Kirabo A., et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest. 2016, 126:50-67.
68. Itani H.A., Xiao L., Saleh M.A., et al. CD70 Exacerbates Blood Pressure Elevation and Renal Damage in Response to Repeated Hypertensive Stimuli. Circ Res. 2016, 118:1233-1243.
69. Fraser A., Nelson S.M., Macdonald-Wallis C., et al. Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation. 2012, 125:1367-1380.
70. Skjaerven R., Wilcox A.J., Klungsoyr K., et al. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study. BMJ. 2012, 345:e7677.
71. Kaptoge S., Di Angelantonio E., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010, 375:132-140. Emerging Risk Factors Collaboration.
72. Sesso H.D., Buring J.E., Rifai N., et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003, 290:2945-2951.
73. Hage F.G. C-reactive protein and hypertension. J Hum Hypertens. 2014, 28:410-415.
74. Youn J.C., Yu H.T., Lim B.J., et al. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013, 62:126-133.
75. Barbaro N.R., Fontana V., Modolo R., et al. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press. 2015, 24:7-13.
76. Devalliere J., Charreau B. The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol. 2011, 82:1391-1402.
77. Saleh M.A., McMaster W.G., Wu J., et al. Lymphocyte adaptor protein LNK deficiency exacerbates hypertension and end-organ inflammation. J Clin Invest. 2015, 125:1189-1202.
78. Huan T., Meng Q., Saleh M.A., et al. Integrative network analysis reveals molecular mechanisms of blood pressure regulation. Mol Syst Biol. 2015, 11:799.
79. Herrera J., Ferrebuz A., Macgregor E.G., et al. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006, 17:S218-S225.
80. Yoshida S., Takeuchi T., Kotani T., et al. Infliximab, a TNF-alpha inhibitor, reduces 24-h ambulatory blood pressure in rheumatoid arthritis patients. J Hum Hypertens. 2014, 28:165-169.
81. Angel K., Provan S.A., Gulseth H.L., et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010, 55:333-338.
82. Sander M., Lyson T., Thomas G.D., et al. Sympathetic neural mechanisms of cyclosporine-induced hypertension. Am J Hypertens. 1996, 9:121S-138S.
83. Yang J., Sundrud M.S., Skepner J., et al. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 2014, 35:493-500.